GlassScriptPhysician profile
Vikramsinh Dabhi
NPI 1609923879
$3,193.77
in general payments reported to CMS, 2019-2025
8 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $110 · 2022: $250 · 2023: $139 · 2024: $2,695.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,695 · Food and Beverage: $118 · Education: $21.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,695.00 |
| Food and Beverage | $117.73 |
| Education | $21.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $1,495.00 | 2024 | Alunbrig |
| Beigene USA, INC. | $675.00 | 2024 | Brukinsa |
| Astrazeneca Pharmaceuticals LP | $525.00 | 2024 | Tagrisso |
| Amgen INC. | $125.00 | 2022 | |
| Eisai INC. | $124.99 | 2022 | |
| Foundation Medicine, INC. | $117.73 | 2023 | |
| Myovant Sciences INC. | $110.05 | 2021 | |
| Mirati Therapeutics, INC. | $21.00 | 2023 | Krazati |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vikramsinh Dabhi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.